EGFR and non-small cell lung carcinoma: Systematic analysis of the latter is endowed with serious difficulties, mainly the rarity and generally better prognosis of the disease compared to EGFR+ and wild-type NSCLC (7), which necessitate longer study intervals in order to recruit sufficient patient numbers, the multitude of ALK-directed compounds, which are used in variable order, as well as the rapidly changing landscape of regulatory approval, which influences the availability and prioritization of various drugs.